Summit Therapeutics' Lung Cancer Drug Shows Survival Benefit
Summit Therapeutics (SMMT) announced that its partner Akeso reported positive overall survival results for ivonescimab in the Phase III HARMONi-2 study. The drug demonstrated a statistically significant improvement in overall survival compared to pembrolizumab among patients with PD-L1-positive non-small cell lung cancer. The trial's success marks an important milestone for Summit Therapeutics and Akeso, as it suggests ivonescimab could offer a more effective treatment option. The results may influence future clinical guidelines and increase investor confidence in the drug’s potential to capture market share in oncology treatments.
Tickers: $SMMT
Topics: cancer treatment immunotherapy pharma